News from janssen r A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 25, 2015, 08:57 ET

INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia, Now Commercially Available

The first schizophrenia treatment to be taken just four times a year – with dosing measured in seasons, not days – is now available in...

Jun 06, 2015, 10:00 ET

New Data Show Initial Use of Canagliflozin in Combination with Metformin Extended Release Significantly Improves A1C Levels in Adults with Type 2 Diabetes

 Janssen Research & Development, LLC (Janssen) today announced results of a phase 3, randomized study showing that the use of initial...

Jun 05, 2015, 11:50 ET

Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma

Janssen Research & Development, LLC (Janssen) has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to...

Jun 03, 2015, 08:07 ET
Television and film actress Megan Park announced that she lives with rheumatoid arthritis (RA), marking the first time she has publicly disclosed living with a chronic autoimmune disease. Park made the announcement in partnership with Joint Decisions.

Actress Megan Park Shares Private Struggle With Rheumatoid Arthritis For The First Time Through "Joint Decisions" Educational Program

 Television and film actress Megan Park today announced that she lives with rheumatoid arthritis (RA), marking the first time she has publicly...

Jun 01, 2015, 17:00 ET

Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma

 Janssen Research & Development, LLC (Janssen) announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant...

Jun 01, 2015, 16:22 ET
Jun 01, 2015, 12:04 ET
May 30, 2015, 07:32 ET

Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia

 Data from the Phase 3 CLL3001 (HELIOS) trial demonstrated that the combination of ibrutinib (IMBRUVICA®) plus bendamustine and rituximab...

May 30, 2015, 07:31 ET

Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients

 Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent...

May 28, 2015, 08:30 ET

New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

 Janssen Pharmaceuticals, Inc. (Janssen) and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new...

May 22, 2015, 11:05 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Janssen reçoit un avis favorable de la part du CHMP à la recommandation d'IMBRUVICA® (Ibrutinib) pour le traitement de la macroglobulinémie de Waldenström

Ce communiqué de presse a été rédigé en Anglais.  Des traductions en Allemand, Français et Espagnol sont...

May 22, 2015, 11:04 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Janssen erhält positive Stellungnahme des CHMP, das IMBRUVICA® (Ibrutinib) zur Behandlung von Morbus Waldenström empfiehlt

Die Originalsprache dieser Pressemitteilung ist Englisch. Übersetzungen ins Deutsche, Französische und Spanische werden von PR Newswire...

May 22, 2015, 10:52 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Janssen recibe comentarios positivos del CHMP al recomendar IMBRUVICA® (Ibrutinib) para el tratamiento de la macroglobulinemia de Waldenström

Este comunicado de prensa está originalmente escrito en inglés. PR Newswire proporciona las traducciones en alemán, francés y...

May 21, 2015, 08:00 ET

PREZCOBIX™ (darunavir/cobicistat) aprobado en EE. UU. para el tratamiento de adultos que viven con VIH-1

 Janssen Therapeutics, una División de Janssen Products, LP (Janssen), anunció hoy que la Administración de Alimentos y...

May 19, 2015, 16:05 ET
Janssen Logo.

Janssen Enters into a Worldwide Collaboration with Achillion Pharmaceuticals, Inc. to Combat Hepatitis C Virus

Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered...

May 19, 2015, 08:17 ET

U.S. FDA Approves INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia

 There's a new treatment option for schizophrenia – INVEGA TRINZA™ (three-month paliperidone palmitate), the first and only...

May 18, 2015, 08:30 ET

New Real-World Data Show Adults with Type 2 Diabetes, Including Those Taking Multiple Diabetes Medications, Achieve Blood Glucose Treatment Goals After Using INVOKANA® (canagliflozin)

 Janssen Pharmaceuticals, Inc. (Janssen) today announced results from three real-world analyses, which found significant improvements in blood...

May 15, 2015, 08:00 ET

Real-World Data Presented at American Geriatrics Society Meeting Show Consistent Safety of XARELTO® in Elderly Patients

New data from an ongoing post-marketing study evaluating the safety of once-daily XARELTO® (rivaroxaban) in patients with non-valvular atrial...

May 14, 2015, 14:46 ET

New Data on XARELTO® Versus Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

 Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced results from the VENTURE-AF trial. The study...